Tag Archive for: GBS

MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults

Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults and older adult population with co-morbidities First immunological read-outs are anticipated in Q4, 2023 Copenhagen, Denmark, 27 June 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today […]

MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults

Expands development of novel GBS vaccine in older adult population Targeting significant and growing unmet medical need of GBS infection Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first phase 1 clinical study in older adults of its […]

MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine

Newly appointed CMO with more than 25 years’ experience in vaccine development Fast Track status granted by US Food and Drug Administration Completion of enrolment of its 2nd phase II clinical trial in pregnant women Copenhagen, Denmark, 5 January 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B […]

MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus

Financing from new investors Trill Impact Ventures and Pureos Bioventures as well as existing investors Backing from European Investment Bank Planning for Phase 3 clinical development of novel GBS vaccine Copenhagen, Denmark, 15 December 2022 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the […]